Near-infrared Optical Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model  by Zhao, Dawen et al.
Near-infrared Optical Imaging
of Exposed Phosphatidylserine
in a Mouse Glioma Model1
Dawen Zhao*, Jason H. Stafford†, Heling Zhou*
and Philip E. Thorpe†
*Department of Radiology, UT Southwestern Medical
Center, Dallas, TX, USA; †Department of Pharmacology,
UT Southwestern Medical Center, Dallas, TX, USA
Abstract
Phosphatidylserine (PS) is normally intracellular but becomes exposed on the luminal surface of vascular endothelial
cells in tumors. It also becomes exposed on tumors cells responding to therapy. In the present study, we optically
imaged exposed PS in vivo using PGN635, a novel monoclonal antibody that binds PS. The F(ab′)2 fragment of
PGN635was labeled with the near-infrared (NIR) dye, IRDye800CW. In vivo dynamic NIR imagingwas performed after
injection of 800CW-PGN635 into mice bearing radiation-treated or untreated U87 glioma xenografts growing sub-
cutaneously or orthotopically. NIR optical imaging revealed a clear tumor contrast in nonirradiated subcutaneous U87
gliomas after injection of 800CW-PGN635. The tumor contrast was visible as early as 4 hours later and was maximal
24 hours later (tumor-to-normal tissue ratio [TNR] = 2.8 ± 0.7). Irradiation enhanced the tumor contrast at 24 hours
(TNR = 4.0 ± 0.3). Similar results were observed for orthotopic gliomas. Localization of 800CW-PGN635 to tumors
was antigen specific because 800CW-Aurexis, a control probe of irrelevant specificity, did not localize to the tumors,
and preadministration of unlabeled PGN635 blocked the uptake of 800CW-PGN635. Fluorescence microscopy con-
firmed that 800CW-PGN635 was binding to PS-positive vascular endothelial cells in nonirradiated gliomas. Irradiation
of the gliomas increased PS exposure on both tumor vascular endothelial cells and tumor cells and gave rise to an
increase in tumor contrast with 800CW-PGN635 that was predictive of the reduction in tumor growth. 800CW-
PGN635 may be a useful new imaging probe for detection of exposed PS in tumors responding to therapy.
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Introduction
Molecular imaging can provide useful information about drug develop-
ment, patient stratification, and response to therapy [1–3]. Successful
cancer imaging requires imaging probes that recognize cancer-specific
markers with great specificity and sensitivity. Cell surface–exposed phos-
phatidylserine (PS) is an attractive target for molecular imaging. PS is
strictly located in the inner leaflet of the plasmamembrane bilayer inmost
normal cell types, including the vascular endothelium. Loss of PS asym-
metry occurs during apoptosis and necrosis, resulting in the exposure of
PS on the external surface of the cells [4]. Much interest has been gener-
ated in developing molecular imaging probes that bind to the exposed
PS to noninvasively monitor the response of patients’ tumors to various
treatments from the induction of tumor apoptosis. Annexin V (A5) is the
PS-binding ligand that is most widely used for this purpose. Various
radiotracers have been conjugated to annexin V for positron emission
tomography (PET) or single-photon emission computed tomography
(SPECT) imaging in preclinical tumor models and cancer patients [5,6].
It has recently been observed that PS becomes exposed on the outer
surface of viable (nonapoptotic) endothelial cells in tumor blood
vessels, probably in response to oxidative stresses present in the tumor
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microenvironment [7,8]. Vascular endothelium in normal tissues
does not have exposed PS. Thus, in addition to imaging apoptotic
tumor cells, PS-binding probes also image the exposed PS on the
tumor vasculature. We have developed a series of monoclonal anti-
bodies that recognize PS with higher specificity than does annexin
V [7–10]. The antibodies recognize PS complexed with the PS-binding
protein, β2-glycoprotein 1 (β2GP1) [10]. The murine antibodies 2aG4
and 3G4 localize to PS-positive blood vessels in multiple tumor models
[9,11,12]. The antibodies then induce monocytes to bind to the tumor
vasculature and destroy it by antibody-dependent cellular cytotoxicity,
leading to tumor growth inhibition [9,12,13]. Antitumor effects of these
antibodies are enhanced by chemotherapy [11], radiation [12,13], and
hormone-deprivation therapy [14], all of which increase levels of exposed
PS in the tumors, and amplify the target for attack by the antibodies.
Bavituximab, a chimeric monoclonal PS-targeting antibody, is in ad-
vanced clinical trials in patients with lung and breast cancer [15,16].
In the present study, we used a new, fully human PS-targeting anti-
body, PGN635, which is similar in specificity and affinity to bavituximab
(K d ≈ 10
−10 M). Like bavituximab, PGN635 recognizes exposed PS
complexed with the PS-binding plasma protein β2GP1 [10]. To detect
PS, we conjugated the F(ab′)2 fragment of PGN635 with an NIR dye,
IRDye800CW, and used optical imaging to study exposed PS on sub-
cutaneous or orthotopic U87 gliomas in athymic mice. Optical imaging
is an inexpensive and rapid technique that allows real-time measurements
to be made of exposed PS in vivo. NIR dyes have advantages over visible
fluorophores in that they use excitation and emission wavelengths in
the NIR range. NIR light penetrates tissues more deeply than visible light
and causes minimal autofluorescence. The NIR dyes therefore allow im-
aging of deep-seated orthotopic gliomas in the mouse brain [17–19]. To
explore whether 800CW-PGN635 could be used to monitor dynamic
changes in levels of exposed PS, gliomas were imaged before and after
irradiation. Exposed PS was elevated by irradiation, with the maximal
tumor-to-normal tissue ratio (TNR) being obtained 24 hours after
irradiation. Fluorescence microscopy revealed that irradiation induces
PS to become exposed on both the vasculature and the tumor cells them-
selves. Our findings suggest that 800CW-PGN635 is a useful tool with
which to study exposed PS in preclinical animal tumors. These
experiments lay the foundation for further development of PGN635
as an imaging agent in clinic.
Materials and Methods
Preparation of PGN635 F(ab′)2 Fragments and Labeling
with IRDye800CW
The human monoclonal antibody PGN635 was generated by
Affitech A.S. (Oslo, Norway) in collaboration with Peregrine Pharma-
ceuticals, Inc (Tustin, CA). It was produced under serum-free condi-
tions by Avid Bioservices (Tustin, CA). Aurexis is a human monoclonal
antibody that binds to an irrelevant antigen (Staphylococcus aureus
clumping factor A) and was used as a negative control antibody.
PGN635 and Aurexis F(ab′)2 fragments were generated by reacting
antibodies with pepsin at a molar ratio of 1:130 (antibody-pepsin)
for 1 hour at 37°C. F(ab′)2 fragments (MW = 110 kDa) were purified
by FPLC using an S-200 column (Pharmacia, Piscataway, NJ) and PBS
running buffer. F(ab′)2 was then reacted with an N -hydroxysuccinimide
ester derivative of IRDye800CW (Li-COR, Lincoln, NE) at a molar
ratio of 1:10 (F[ab′]2-dye) for 2 hours at room temperature. Unreacted
dye was separated from the conjugate using a PD-10 desalting column
(GEHealthcare, Uppsala, Sweden). Analyses of the final product, based
on the absorbance of the dye at 778 nm and the absorbance of the F(ab′)2
at 280 nm, showed that it consisted of approximately two molecules of
dye bound to each F(ab′)2 fragment. The products are referred to as
800CW-PGN635 or 800CW-Aurexis throughout the article.
Glioma Models
All animal procedures were approved by the Institutional Animal
Care and Use Committee of University of Texas Southwestern
Medical Center. Subcutaneous models were established by injecting
2 × 106 human U87MG glioma cells (ATCC,Manassas, VA) in 100 μl
of serum-free medium containing 25% Matrigel (BD Biosciences,
San Jose, CA) subcutaneously on the right thigh of anesthetized nude
mice (n = 4; BALB/c nu/nu; Harlan, Indianapolis, IN). For radiation
studies, the total of 20mice included 8 mice implanted with tumor cells
on both thighs for imaging study and 12mice with one thigh tumor for
tumor growth study. Orthotopic gliomas were established by making a
1-cm-long incision along the midline of the head of anesthetized nude
mice (n = 6) to expose the skull. Using a high-speed drill, a 1-mm burr
hole was made in the skull over the right hemisphere, anterior to the
coronal fissure. About 105 U87 cells in 4 μl of PBS and Matrigel were
injected directly into right caudal diencephalon 1.5mm beneath the dura
mater using a 32-gauge Hamilton syringe that causes minimal tissue
damage. The burr hole was filled with bone wax, and the scalp was closed
with sutures.
Radiation Treatment
When subcutaneous tumors on both thighs reached ∼5 mm in
diameter, a single dose of 12 Gy of irradiation was delivered to the
tumors on the left thigh of anesthetized mice using a small animal
irradiator (XRAD320; Precision X-ray, Inc, North Branford, CT) fitted
with a variable collimator to generate a single adjustable collimated
iso-dose beam of x-rays at a dose rate of 10 Gy/min. In a separate
experiment, six animals bearing single subcutaneous tumors (∼5 mm
in diameter) received a single dose of 12 Gy of radiation to their tumors,
whereas another group of six tumor-bearing animals served as controls.
Tumor size was measured using calipers twice a week, and tumor
volume was calculated using abc × 6/π. For the orthotopic gliomas, a
single dose of 12 Gy of irradiation was delivered using a D-shaped
collimator to the whole brain excluding the olfactory bulb.
Detection and Quantification of Exposed PS In Vivo
Mice bearing two thigh tumors were given a single dose of 12 Gy
of irradiation to the left tumor to induce exposed PS. Twenty-four
hours later, 150 μg of PGN635 or the control body Aurexis was in-
jected intravenously (i.v.) and allowed to circulate for 4 hours. The
mice were anesthetized, exsanguinated, and perfused with heparin-
ized saline. The tumors on both sides and adjacent muscular tissues
were removed and frozen for preparation of cryosections. Vascular
endothelium was stained using a rat antimouse CD31 antibody
(BD Biosciences, San Jose, CA) followed by Cy3-labeled goat anti-rat
IgG. PGN635 or Aurexis was detected using biotinylated goat anti-
human IgG conjugated toCy2. Images were captured using aCoolSNAP
digital camera (Roper Scientific Photometrics, Tucson, AZ) mounted
on Elipse E600 fluorescent microscope (Nikon, Melville, NY) and
analyzed with MetaVue software (Universal Imaging Corporation,
Downingtown, PA). Doubly labeled endothelial cells (i.e., CD31 positive/
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PGN635 positive) were identified by yellow fluorescence on merged
images. The percentage of doubly positive vessels was calculated as follows:
(mean number of yellow vessels per field / mean number of total vessels) ×
100. Ten random 0.079-mm2 fields were evaluated for each section.
Magnetic Resonance Imaging
Orthotopic gliomas were examined by anatomic magnetic resonance
imaging (MRI) using a 9.4-T horizontal bore magnet with a Varian
INOVA Unity system (Palo Alto, CA). Each mouse was maintained
under general anesthesia (air and 2% isoflurane). T1- and T2-weighted
fast spin-echo multislice coronal images were acquired. T1-weighted
contrast-enhanced images were acquired after i.v. bolus injection of
the contrast agent Gd-DTPA-BMA (0.1 mmol/kg body weight;
Omniscan [Amersham Health, Inc, Princeton, NJ]) into a tail vein.
NIR Fluorescence Imaging
When the subcutaneous tumors reached ∼5 mm in diameter,
in vivo fluorescence imaging was performed using a Maestro imaging
system (CRi, Inc, Woburn, MA). Each mouse was maintained under
general anesthesia (air and 2% isoflurane). NIR images were acquired
before and at different times after administration of 800CW-PGN635
or 800CW-Aurexis (2 nmol/mouse) through a tail vein. For the irradi-
ated tumors, the NIR dye–labeled conjugates were injected 24 hours
after irradiation, and imaging was carried out periodically for 24 hours.
For the antibody competition study, unlabeled PGN635 was injected
i.v. at 2.5 mg/kg 4 hours before administration of 800CW-PGN635.
A set of filters specifically for NIR imaging (excitation, 671-705 nm;
emission, 730-950 nm) was applied. For the orthotopic gliomas, NIR
imaging was initiated after MRI confirmed an intracranial tumor with a
diameter of ∼5 mm. The tumor-bearing mice were anesthetized and
imaged for 24 hours. Immediately after the last image at 24 hours,
the skull of the mouse was surgically removed to expose both sides of
the brain tissues and a last in vivo image was obtained. The whole sur-
gical procedure and imaging were completed within 10 minutes under
anesthesia, and no obvious bleeding occurred.
Analysis of Fluorescence Imaging
Fluorescence images were processed with the Maestro software 2.8.
The spectrum of background signal (peak emission, ∼770 nm) was
first obtained from a mouse before the 800CW-antibody conjugate
injection, whereas the spectrum of 800CW conjugates (peak emission,
∼800 nm) was detected from a solution of the dye in PBS. The spectra
Figure 1. Immunohistochemical study of localization of PGN635 antibody in nonirradiated and irradiated tumors. Mice bearing a sub-
cutaneous U87 glioma on each thigh received a single dose of 12 Gy of irradiation to the left side tumor. Exposure of PS was determined
24 hours later by i.v. injection of full-length PGN635 or control antibody Aurexis. Animals were perfused with saline 3 hours later. (A)
Frozen sections of nonirradiated and irradiated tumors were analyzed for the presence of fluorescently labeled PGN635 (green). Vascular
endothelial cells were counterstained with anti-CD31 (red). Merged images revealed coincidence of staining showing that PGN635 was
bound to vascular endothelial cells in the nonirradiated tumor. Increased PGN635 staining was seen in the irradiated tumors and was
due to increased staining of both endothelial cells and tumor cells. Tumor sections from control animals that had been injected with
Aurexis were essentially unstained (not shown). (B) The tumor tissues and adjacent muscular tissues, both of which received a single
dose of 12 Gy of radiation, were used for PGN635 staining. In contrast to abundant positive staining seen in tumor vessels, the muscle
showed essentially no positively stained vessels. (C) Irradiation increased the percentage of PS-positive vessels from 27% ± 10% to
64% ± 6% (P < .001). Staining with PGN635 was antigen specific because Aurexis gave low levels of staining.
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were then imported and used to unmix the NIR dye signal from the
background signal for both in vivo and ex vivo studies. The whole set of
in vivo images of each individual mouse, obtained before and at various
times after injection of the dye, was examined for quantification. A
common region of interest was based on the most obvious signal of
the tumor 24 hours after injection and was applied to both the tumor
and the normal tissue of each image. Because exposure time of light
varied at different time points, longer exposure times were used for
the later time points. The total photon counts were normalized by time
(counts/sec) in identical regions of interest and compared to each other
to detect dynamic changes in signal intensity. These data were used to
construct the histograms in the figures.
Ex Vivo Fluorescence Imaging
Immediately after the last in vivo image, tumor-bearing mice were
killed, and tumor tissues and thigh muscles were dissected. Ex vivo
fluorescence imaging was performed using theMaestro imaging system.
NIR Fluorescence Microscopy
Immediately after in vivo imaging, tumor-bearing mice were killed,
and tumor tissues were dissected. The cryosections were immunostained
with antibodies to the endothelial marker, CD31 (Serotec, Raleigh, NC)
followed by Cy3-conjugated secondary antibody (Jackson Immuno-
research Laboratories, West Grove, PA). The NIR fluorescence signal
was detected using a Zeiss AxioObserver (Carl Zeiss MicroImaging,
Inc, Thornwood, NY) equipped with NIR filters. The NIR signals were
recorded and merged with the CD31 image and the 4′, 6-diamidino-2-
phenylindole (DAPI)–stained image of the same field.
Statistical Analysis
Statistical significance was assessed using an analysis of variance
on the basis of the Fisher protected least significant difference (StatView;
SAS Institute, Inc, Cary, NC) or Student’s t tests.
Results
Exposed PS on Blood Vessels and Tumor Cells in Gliomas
An average of 27% ± 10% of blood vessels in nonirradiated
tumors had exposed PS on their endothelium, as judged by coincident
staining of vessels by PGN635 and anti-CD31 (Figure 1, A-C). Irradi-
ation increased the levels of exposed PS on tumor vessels to 64% ± 6%
(P < .001; Figure 1). In addition, irradiation induced PS exposure on
Figure 2. In vivo NIR imaging of baseline level of PS in a subcutaneous glioma. (A) A mouse bearing a representative subcutaneous U87
glioma on the right thigh (arrow) was injected i.v. with 800CW-PGN635, and optical imaging was performed at various time points
thereafter. During the first 4 hours, the light signal accumulated in the tumor area. However, by 24 hours, the light signal remained only
in the tumor and persisted there for at least 48 hours after injection. (B) Mean light intensity curves for the tumor (open circles) and the
contralateral muscle (solid squares) revealed that 800CW-PGN635 rapidly gave signals in both the tumor and the normal muscle but that
the tumor signal was sustained while the muscle signal had washed out by 24 hours. The tumor-muscle ratios were 2.2 at 24 hours and
2.4 at 48 hours. (C) Normalized emission spectra showing the NIR PGN635 dye with a peak emission wavelength at ∼800 nm (red),
whereas the background signal wavelength (white) was at ∼770 nm.
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the tumor cells themselves (Figure 1A). Tumor cells were identified by
their expression of human histocompatibility antigens, as detected by
staining with W6/32 antibody (not shown). The localization seen with
PGN635 to vessels and tumor cells was antigen specific because the
negative control 800CW-Aurexis produced relatively little staining
(Figure 1C ). Furthermore, muscular tissues adjacent to the tumor
that received the 12-Gy radiation were found to be essentially devoid
of PGN635 staining, compared to the abundant PGN635 staining
seen in tumor tissues (Figure 1B).
In Vivo Optical Imaging of Exposed PS
in Nonirradiated Gliomas
800CW-PGN635 localized with high selectivity to subcutaneous
U87 tumors in mice. Clear contrast between the tumor and contra-
lateral normal tissue was visible 24 hours after injection and improved
still further by 48 hours after injection (Figure 2A). Time course stud-
ies showed that the light intensity in both the tumor and the normal
tissue was maximal 5 minutes after injection and then decreased
abruptly during the next 4 hours. However, in contrast to the fast wash-
out in normal tissues, the signal in the tumor was maintained over time.
The TNR was 2.2 at 24 hours and 2.4 at 48 hours (Figure 2B). The
800CW-labeled F(ab′)2 fragment of PGN635 antibody is cleared from
the blood with a half-life of 6 hours (J.H.S., unpublished observations).
Thus, the images shown in Figure 2 represent tumor-bound label. Nor-
malized emission spectra of 800CW-PGN635 and background are
shown in Figure 2C .
Dynamics of Exposed PS in Response to Radiation
A single dose of 12 Gy of irradiation was given to the left side
tumor of mice carrying tumors on each thigh. 800CW-PGN635
was injected 24 hours later. As expected, the nonirradiated tumors
on the right side gave similar results to those of mice with single tumors
(Figure 2) with a maximum TNR of 2.5 ± 0.5 being obtained 24 hours
after injection (P < .05; Figure 3, B and C ). Irradiation significantly
enhanced tumor contrast. A TNR of 2.8 ± 1.1 was obtained 4 hours
after injection, rising to 4.0 ± 0.2 24 hours after injection. The ratio of
the TNR in the irradiated tumors to that in the nonirradiated tumors
was 1.6 at 24 hours after injection. For tumor growth study, the tumors
Figure 3. In vivo NIR imaging of exposed PS in gliomas before and after irradiation. (A) A mouse bearing representative size-matched
subcutaneous U87 tumors on each thigh received 12 Gy of irradiation to the left side tumor. (B) At 24 hours after radiation, 800CW-
PGN635 was injected through a tail vein, and a series of in vivo fluorescence images was acquired at different time points. The contrast
between the nonirradiated tumor on the right side and normal muscle increased during the 24-hour period after injection to a TNR of 2.6.
Irradiation of the tumor on the left side increased levels of exposed PS to a TNR of 4.2. *P < .05 from non-IR. (C) A time course study
revealed that the maximal TNR of 2.5 was achieved at 24 hours for nonirradiated tumors (n = 4; blue line). Irradiation increased the TNR
of the irradiated tumor to 4.0 at 24 hours (n = 4; red line; P < .05). (D) Tumor growth curves showed that a single dose of 12 Gy of
radiation significantly inhibited tumor growth (n = 6), compared with the sham irradiated control tumors (n = 6; **P < .01).
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(n = 6) received a single dose of 12 Gy of radiation showed significantly
inhibited tumor growth compared with the sham control group (n = 6;
P < .01; Figure 3D).
Specificity of 800CW-PGN635
The binding specificity of 800CW-PGN635 was confirmed by
comparing its localization pattern with that of the negative control
800CW-Aurexis. Figure 4A shows that 800CW-Aurexis entered both
the irradiated and the nonirradiated tumors within 30 minutes of
injection, but rapidly washed out. No significant contrast remained
between either the irradiated or the nonirradiated tumors and normal
tissues by 24 hours (Figure 4B). Furthermore, preadministration of
unlabeled PGN635 before giving the 800CW-PGN635 almost
completely blocked localization of the 800CW-PGN635 to both
irradiated tumors and nonirradiated tumors (Figure 4C ).
In Vivo Optical Imaging of Exposed PS in Orthotopic Gliomas
800CW-PGN635 successfully imaged U87 gliomas growing in
the brains of mice, despite the light having to pass through the skull.
Before optical imaging, MRI revealed that the mice had intracranial
tumors with a high signal intensity on T2-weighted images and a ring-
shaped contrast enhancement on T1-weighted contrast enhanced
images (Figure 5A). A clear light signal that corresponded to the mag-
netic resonance image of the tumor in location and size was obtained
24 hours after injection of 800CW-PGN635 (Figure 5B). The mean
tumor signal was 1.3 ± 0.4 for the nonirradiated tumors and 1.6 ± 0.3
for the 12-Gy irradiated tumors. To confirm that the signal originated
from the brain tumor, a surgical procedure was performed on anesthe-
tized mice to reflect the scalp and remove the skull to expose the brain.
A brighter and more focused light signal was emitted from the region of
tumor growth (Figure 5B). The TNR for irradiated tumors was sig-
nificantly higher (4.2 ± 0.4) compared with that (2.1 ± 0.4) for non-
irradiated brain tumors (P < .01; Figure 5C). The improvement in TNR
and the difference between nonirradiated and irradiated tumors seen
when the skull was removed are probably because both the excitation
light and the emitted light are significantly absorbed during passage
through the skull and scalp.
NIR Fluorescence Microscopy to Detect 800CW-PGN635
in Tumors
A fluorescence microscope equipped with NIR filters was used to
detect 800CW-PGN635 in cryosections (7 μm) prepared from sub-
cutaneous tumors 24 hours after injection of 800CW-PGN635. In
good agreement with histologic findings with unconjugated PGN635
Figure 4. Specificity of 800CW-PGN635 optical probe in vivo. (A) To establish the antigen specificity of the 800CW-PGN635 probe, a
control probe 800CW-Aurexis was injected into the mice 24 hours after irradiating one of the tumors in the flanks. A series of whole
body images was acquired. The 800CW-Aurexis accumulated in both tumors during the first hour. However, both signals diminished
thereafter. No signal remained in either tumor 24 hours after injection. (B) A time course study showed that 800CW-Aurexis did not
accumulate in either the nonirradiated tumors (n = 2) or the irradiated tumors (n = 2). (C) A competition study showed that injection
of unlabeled PGN635 (2.5 mg/kg, i.v.) 4 hours before imaging blocked 800CW-PGN635 accumulation in both the irradiated tumor (left)
and the nonirradiated tumor (right).
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(Figure 1), merged images showed that the 800CW-PGN635 was essen-
tially binding exclusively to vascular endothelial cells in nonirradiated
tumors (Figure 6). Irradiation increased the percentage of PS-positive
vessels and also induced exposed PS on the tumor cells themselves.
Thus, the 800CW-PGN635 signal in nonirradiated tumors derives
from PS-positive vasculature, whereas the stronger signal in irradiated
tumors derives from both PS-positive vasculature and tumor cells.
Discussion
We have demonstrated the feasibility of using PGN635 F(ab′)2 labeled
with the NIR dye, 800CW, for optical imaging of exposed PS in both
subcutaneous and orthotopic mouse models of U87 glioma. Histologic
studies showed that the PS signals detected in nonirradiated gliomas by
in vivo NIR imaging were due to exposed PS on tumor vascular endo-
thelial cells. This is in good agreement with previous studies performed
in various tumor models: prostate R3327-AT1 tumors [30], breast
cancer MDA-MB231, 4T1 cells [31], lung cancer H460 and A549,
and F98 gliomas [12,13]. Irradiation-induced increase in exposed PS
was successfully visualized by 800CW-PGN635 optical imaging in
mice. Fluorescence microscopy confirmed that both PGN635 and
800CW-PGN635 localized more strongly to the irradiated tumors.
In irradiated tumors, both the vessels and the tumor cells were PS pos-
itive. The antigen-binding specificity of PGN635 was verified by com-
petition experiments with unconjugated PGN635 and by the lack of
staining with the irrelevant control 800CW-Aurexis.
Noninvasive molecular imaging of apoptosis is of clinical im-
portance because it could give an early indication of the responsive-
ness of a patient’s tumor to therapy, allowing alterations in the
therapy to be made if the responses were not as good as expected
[5,6,20]. In the past several years, much effort has been made in
developing molecular imaging agents to monitor tumor responses.
Radiolabeled and fluorescent annexin V preparations have been
extensively tested in animal studies [21–23]. More recently, clinical
studies of PET or SPECT imaging with radiolabeled annexin V have
shown that a higher uptake of annexin V by tumors during or after
treatment correlates positively with a better prognosis in patients
with breast, head and neck, or lung cancer [24–26]. However, not
all PS-expressing tumor cells in responding tumors are apoptotic.
Hammill et al. [27] found that many of the cells that stain positively
for annexin V are viable and can resume growth and reestablish phos-
pholipid asymmetry once the therapy is discontinued. Their results
indicate that exposed PS, and thus loss of membrane asymmetry, pre-
cedes commitment to apoptotic death.
PGN635, bavituximab, and related murine monoclonal antibodies
recognize PS and other anionic phospholipids in a β2GP1-dependent
fashion. The antibodies have a more restricted specificity for PS than
does annexin V, which recognizes PE in addition to PS and other anionic
phospholipids [7,28,29]. We previously radiolabeled bavituximab with
74As, which is a long-lived positron emitter having a radioactive half-life
of 17.8 days, and used it to image the vasculature of Dunning prostate
R3227-AT1 tumors in rats. The long half-life of 74As allowed the intact
Figure 5. In vivo optical imaging of exposed PS in orthotopic gliomas. A mouse bearing a representative orthotopic U87 glioma was
irradiated with a single dose of 12 Gy to the whole brain using a D-shaped collimator. (A) Anatomic MRI revealed a 5-mm-diameter
intracranial lesion crossing the midline to invade the left side brain on the consecutive T2-weighted slices. T1-weighted contrast-enhanced
MRI showed the typical ring-shaped enhancement in the tumor periphery. (B) 800CW-PGN635 was injected into the mouse 24 hours after
radiation, and dynamic NIR optical imaging was performed. As with the subcutaneous tumors, maximal tumor contrast was achieved
24 hours after injection. Removal of the skull increased the signal, and subsequent dissection confirmed that the signal was from the
tumor. (C) The tumor-versus-contralateral normal brain ratio TNR was 4.2 ± 0.4 for irradiated tumors (n = 3), which was significantly
higher than the TNR of 2.1 ± 0.4 for nonirradiated tumors (n = 3; P < .01).
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antibody to reach its optimal target to background selectivity at 72 hours
without appreciable radioactive decay [30]. Tumor-selective targeting
was observed by PET imaging. A maximum tumor-to-liver ratio of 22
was achieved.
In the present study, we used the F(ab′)2 fragment of PGN635 for
optical imaging to ensure its rapid clearance from the bloodstream and
the achievement of high tumor to background ratios by 24 hours after
injection. Because the target on vascular endothelial cells is directly
accessible to the blood, PGN635 localizes rapidly to tumor vessels.
We have previously demonstrated that exposed PS on tumor vessels
in orthotopic gliomas is freely accessible to PS-targeting antibodies
[12]. Even tumor cells having exposed PS were labeled, probably
because local disruption of blood brain barrier occurs in brain tumors.
PGN635 is not internalized to any significant extent by cells and so
remains for 2 to 3 days on the endothelial cell surface, giving plenty
of time for the unbound PGN635 F(ab′)2 in the blood to be cleared.
We found in the present study that PGN635 labels about 27% of the
vessels in nonirradiated U87 gliomas. Different tumors vary in the
percentage of their vessels that have exposed PS [7,8,12,13,30]. In
Dunning R3227-AT1 prostate tumors, 40% of vessels have exposed
PS [30]. In F98 gliomas, the percentage is only 11% [12]. Exposed PS
on viable endothelial cells is induced by hypoxia, acidity, and other
stresses known to be present in the tumor microenvironment [7]. Dif-
ferences in PS positivity in different tumors probably relate to the
levels of oxidative stresses in the tumor microenvironment [31].
Irradiation of U87 tumors with 12 Gy increased the percentage of
tumor vessels that had exposed PS from 27% to 64% and increased
the TNR from 2.8 to 4.0. These findings accord with our earlier
finding that irradiation of A549 NSCLC xenografts and F98 gliomas
increase vascular expression of PS [12,13]. We have previously applied
fractionated radiation (2 Gy × 5) to treat H460 lung tumor xenografts.
Similar to our current study, the fractionated radiation sufficiently in-
duced PS exposure [13]. Endothelial cells in tumors are highly sensitive
to irradiation and expose PS after as little as 5 Gy. Our previous studies
have shown that endothelial cells in tumors irradiated with 5 Gy seem
to remain viable. They remain morphologically intact and lack markers
of apoptosis for several days [13]. In the present study, 12 Gy of irra-
diation also increased PS exposure on the tumor cells in U87 tumors,
thus contributing to the increased localization of 800CW-PGN635 in
irradiated tumors. Further studies are needed to determine whether the
PS-expressing tumor cells are apoptotic or not.
Optical imaging is increasingly being used in preclinical cancer
research [32,33]. It is being used in particular to study cancer-specific
markers and drug pharmacokinetics and to monitor drugs’ effects in
small animals [17,34,35]. The attraction of the technique is that it is
inexpensive, is simple to conduct, gives real-time results, and does not
require the handling and disposal of radioactive isotopes. In the clinic,
optical imaging by visualizing fluorescently labeled tumor cells has
recently emerged as an attractive approach to facilitate identification
of tumor margins or sentinel lymph node metastases [36,37]. Several
Figure 6. NIR fluorescence microscopy to detect the location of the 800CW-PGN635 optical probe in nonirradiated or irradiated gliomas.
(A) Mice bearing subcutaneous gliomas that had been irradiated (IR) or sham-irradiated (non-IR) were injected with 800CW-PGN635
24 hours later. Irradiation increased the tumor signal. The gliomas and contralateral muscle (mu) were excised. (B) Sections of non-
irradiated (top row) or irradiated U87 gliomas (bottom row) were examined for the presence of 800CW-PGN635 (red), CD31 (green)
or DAPI (blue). Vascular endothelial cells were detected by immunofluorescence staining with anti-CD31 (green). Nuclei were detected
with DAPI (blue). NIR signals were detected with an infrared filter. The merged image shows that the PGN635 optical probe colocalized
with tumor vascular endothelial cells in the nonirradiated tumor. In contrast, irradiation increased the NIR signal on both the vascular
endothelial cells and the tumor cells.
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previous studies have demonstrated in vivo optical imaging of apoptosis
with annexin V labeled with Cy5.5, a red excitable dye [22]. However,
the NIR dye IRDye800CW seems to be superior to Cy5.5 for in vivo
imaging [34]. NIR fluorescence penetrates more deeply into tissues
because it has lower tissue absorption and scattering of light and
causes relatively little autofluorescence. Our previous study showed
that it is possible to image deep-seated orthotopic gliomas in mice with
IRDye800-labeled 2-deoxyglucose [18]. Here, we have demonstrated
the ability of NIR optical imaging to detect PS translocation in both
subcutaneous and orthotopic glioma models.
Clinical applications of optical imaging are currently limited to the
detection of tumor margins or deposits during surgery, to the detec-
tion of superficial tumors, and to the detection of deep-seated tumors
by endoscopy. The current study is also a proof-of-principle study, in-
dicating the potential of this unique antibody for detecting deep-seated
tumors using PET, SPECT, or MRI. Other labels besides optical dyes
should be considered for attachment to PGN635 F(ab′)2 fragments.
PGN635 is particularly impressive as a targeting ligand because of its
high specificity, lack of uptake by the liver or any other organs, rapid
acquisition by its vascular target, and its persistence on the vascular
target for days. It is an excellent candidate, for example, for labeling
with DOTA and 64Cu for PET or 111In for SPECT. It should have
applications not only in tumor imaging but also in the imaging of
thrombi or sites of ischemia for cardiovascular investigations. It will
also be interesting to correlate PGN635 optical imaging data with func-
tional MRI studies of apoptosis by diffusion-weighted MRI and vas-
cular perfusion or permeability by dynamic susceptibility contrast MRI.
In summary, we have combined NIR optical imaging with
PGN635, a novel monoclonal antibody that binds to PS, to monitor
in vivo dynamics of exposed PS on mouse gliomas. We show that irra-
diation increases the PS signal, predictive of the response to therapy.
The high tumor specificity of PGN635 in the present study under-
scores the prospects of using PGN635 and related antibodies to treat
cancer in humans.
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